Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Rapid Therapeutic Science Laboratories, Inc. (RTSL) Accumulated Expenses (2018 - 2023)

Rapid Therapeutic Science Laboratories' Accumulated Expenses history spans 6 years, with the latest figure at $173856.0 for Q2 2023.

  • For Q2 2023, Accumulated Expenses rose 114.74% year-over-year to $173856.0; the TTM value through Jun 2023 reached $173856.0, up 114.74%, while the annual FY2022 figure was $124736.0, 177.65% up from the prior year.
  • Accumulated Expenses for Q2 2023 was $173856.0 at Rapid Therapeutic Science Laboratories, up from $148907.0 in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $423321.0 in Q2 2020 and bottomed at $34921.0 in Q1 2021.
  • The 5-year median for Accumulated Expenses is $136821.5 (2022), against an average of $175727.2.
  • The largest annual shift saw Accumulated Expenses soared 631.03% in 2019 before it plummeted 91.29% in 2021.
  • A 5-year view of Accumulated Expenses shows it stood at $336829.0 in 2019, then crashed by 86.66% to $44925.0 in 2020, then changed by 0.0% to $44925.0 in 2021, then skyrocketed by 177.65% to $124736.0 in 2022, then soared by 39.38% to $173856.0 in 2023.
  • Per Business Quant, the three most recent readings for RTSL's Accumulated Expenses are $173856.0 (Q2 2023), $148907.0 (Q1 2023), and $124736.0 (Q4 2022).